Texas Permanent School Fund boosted its stake in shares of uniQure (NASDAQ:QURE – Get Rating) by 2.3% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 26,142 shares of the biotechnology company’s stock after acquiring an additional 586 shares during the period. Texas Permanent School Fund’s holdings in uniQure were worth $487,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in QURE. BlackRock Inc. grew its holdings in shares of uniQure by 1.7% during the first quarter. BlackRock Inc. now owns 4,366,736 shares of the biotechnology company’s stock worth $78,908,000 after buying an additional 72,931 shares in the last quarter. State Street Corp grew its holdings in shares of uniQure by 30.4% in the first quarter. State Street Corp now owns 2,813,416 shares of the biotechnology company’s stock valued at $50,838,000 after purchasing an additional 655,732 shares during the period. Vanguard Group Inc. grew its holdings in shares of uniQure by 2.5% in the first quarter. Vanguard Group Inc. now owns 1,209,840 shares of the biotechnology company’s stock valued at $21,861,000 after purchasing an additional 30,053 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of uniQure by 22.8% in the first quarter. JPMorgan Chase & Co. now owns 884,820 shares of the biotechnology company’s stock valued at $15,989,000 after purchasing an additional 164,069 shares during the period. Finally, Privium Fund Management B.V. grew its holdings in shares of uniQure by 4.9% in the first quarter. Privium Fund Management B.V. now owns 493,229 shares of the biotechnology company’s stock valued at $8,913,000 after purchasing an additional 23,196 shares during the period. 86.46% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on QURE. TheStreet lowered shares of uniQure from a “c-” rating to a “d” rating in a report on Tuesday, August 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of uniQure in a report on Thursday, November 3rd. The Goldman Sachs Group dropped their price objective on shares of uniQure from $54.00 to $48.00 and set a “buy” rating for the company in a report on Thursday, November 3rd. Wells Fargo & Company lowered their target price on shares of uniQure from $34.00 to $24.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 9th. Finally, Chardan Capital lowered their target price on shares of uniQure from $65.00 to $60.00 and set a “buy” rating for the company in a research note on Tuesday, August 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.43.
Insider Transactions at uniQure
uniQure Trading Up 7.1 %
Shares of QURE stock opened at $23.00 on Wednesday. The firm has a market cap of $1.08 billion, a PE ratio of -8.55 and a beta of 0.96. uniQure has a 1-year low of $12.52 and a 1-year high of $30.41. The company has a debt-to-equity ratio of 0.24, a current ratio of 7.26 and a quick ratio of 7.20. The company has a 50-day moving average of $19.51 and a two-hundred day moving average of $19.03.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.
- Get a free copy of the StockNews.com research report on uniQure (QURE)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.